following a full submission under the end of life and orphan medicine process:
niraparib (Zejula®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
In a randomised, double-blind, phase III study, niraparib significantly improved progression-free survival compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS / list price that is equivalent or lower.
Medicine details
- Medicine name:
- niraparib (Zejula)
- SMC ID:
- SMC2338
- Indication:
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 May 2021